Diet therapy along with Nutrition Education can Improve Renal Function in People with Stages 3-4 chronic kidney disease who do not have diabetes. (A randomized controlled trial).
Maryam HamidianshiraziMaryam ShafieeMaryam EkramzadehMahsa Torabi JahromiFarzad NikaeinPublished in: The British journal of nutrition (2022)
The current trial investigates the effect of renal diet therapy and nutritional education on the estimated Glomerular Filtration Rate (eGFR), blood pressure, and depression among patients with CKD. A total of 120 CKD patients (stages 3-4) (15<eGFR<60) were randomized into an intensive nutrition intervention group (individualized renal diet therapy plus nutrition counseling: 0.75 g protein/kg/day and 30-35 kcal/kg/day with sodium restriction) and a control group (routine and standard care) for 24 weeks. The primary outcome was the change in the eGFR. Secondary outcomes included changes in anthropometric measures, biochemistry [serum creatinine (Cr), uric acid, albumin, electrolytes, calcium, vitamin D, ferritin, Blood Urea Nitrogen (BUN), and hemoglobin], blood pressure, nutritional status, depression, and quality of life. The eGFR increased significantly in the intervention group compared with the control group (p<0.001). Moreover, serum levels of Cr and the systolic and diastolic blood pressures decreased significantly in the intervention group relative to the control group (p<0.001, p<0.001, and p=0.020, respectively). The nutrition intervention also hindered the increase in the BUN level and the depression score (p=0.045 and p=0.028, respectively). Furthermore, the reduction in protein and sodium intake was greater in the intervention group (p=0.003 and p<0.001, respectively). Nutritional treatment along with supportive education and counseling, contributed to improvements in renal function, blood pressure control, and adherence to protein intake recommendations. A significant difference in the mean eGFR between the groups was also confirmed at the end of the study using analysis of covariance (ANCOVA) (Β=-5.06; 95% CI: -8.203, -2.999).
Keyphrases
- blood pressure
- chronic kidney disease
- small cell lung cancer
- end stage renal disease
- physical activity
- randomized controlled trial
- epidermal growth factor receptor
- uric acid
- healthcare
- tyrosine kinase
- type diabetes
- depressive symptoms
- hypertensive patients
- left ventricular
- metabolic syndrome
- cardiovascular disease
- phase iii
- study protocol
- heart failure
- peritoneal dialysis
- bone marrow
- body mass index
- glycemic control
- smoking cessation
- amino acid
- blood glucose
- patient reported
- atrial fibrillation
- gestational age
- replacement therapy
- placebo controlled